Apogee Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing best-in-class, novel antibody therapeutics for the treatment of immunological and inflammatory (I&I) disorders. By targeting well-established biological drivers, the company aims to reshape the standard of care for patients with dermatological, respiratory, and gastroenterological conditions. Their lead candidate, Zumilokibart (formerly APG777), is currently in clinical development for the treatment of atopic dermatitis, asthma, and eosinophilic esophagitis, with the goal of providing therapies that work better and longer than current treatment options.
